Bridgebio finally gets its cardiomyopathy win
A convincing hit puts approval, and potentially partnerships, on the table.
Big biotech's upcoming clinical priorities
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Lilly signs up Verve to take on Novartis and Amgen
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.
Novo seeks a cardiovascular boost
An outcomes trial could increase demand for Wegovy even further – if pricing, and production, can be worked out.
Novo makes a gene editing move
Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.
Spotlight – J&J takes on Medtronic and Boston in pulsed field ablation
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Key second-quarter clinical readouts for pharma
Lilly’s Alzheimer's and obesity results, outcomes for Novo Nordisk and oncology data for Merck & Co and Astrazeneca.
Daiichi torches Esperion’s Nexletol milestone promises
Despite assurances by Esperion, Daiichi is refusing to pay up after the Clear Outcomes disappointment.